Drug news
AstraZeneca discontinues development of TC 5214 for Major Depreeive Disorder
AstraZeneca has ceased development of its nicotinic channel blocker TC 5214 for which it had collaborated with Targacept as an adjunctive treatment in depression patients who did not respond to initial treatment. In RENAISSANCE 4 and 5 trials TC 5214 did not meet its primary endpoint.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins